Everolimus for Primary Intestinal Lymphangiectasia With Protein-Losing Enteropathy.
Identifieur interne : 001092 ( Main/Exploration ); précédent : 001091; suivant : 001093Everolimus for Primary Intestinal Lymphangiectasia With Protein-Losing Enteropathy.
Auteurs : Michio Ozeki [Japon] ; Tomohiro Hori ; Kaori Kanda ; Norio Kawamoto ; Takashi Ibuka ; Tatsuhiko Miyazaki [Japon] ; Toshiyuki FukaoSource :
- Pediatrics [ 1098-4275 ] ; 2016.
Descripteurs français
- KwdFr :
- Enfant, Entéropathie exsudative (traitement médicamenteux), Entéropathie exsudative (étiologie), Humains, Immunosuppresseurs (administration et posologie), Lymphangiectasie intestinale (), Lymphangiectasie intestinale (diétothérapie), Lymphangiectasie intestinale (traitement médicamenteux), Lymphoedème (), Lymphoedème (diétothérapie), Lymphoedème (traitement médicamenteux), Mâle, Relation dose-effet des médicaments, Régime pauvre en graisses, Études de suivi, Évérolimus (administration et posologie).
- MESH :
- administration et posologie : Immunosuppresseurs, Évérolimus.
- diétothérapie : Lymphangiectasie intestinale, Lymphoedème.
- traitement médicamenteux : Entéropathie exsudative, Lymphangiectasie intestinale, Lymphoedème.
- étiologie : Entéropathie exsudative.
- Enfant, Humains, Lymphangiectasie intestinale, Lymphoedème, Mâle, Relation dose-effet des médicaments, Régime pauvre en graisses, Études de suivi.
English descriptors
- KwdEn :
- Child, Diet, Fat-Restricted, Dose-Response Relationship, Drug, Everolimus (administration & dosage), Follow-Up Studies, Humans, Immunosuppressive Agents (administration & dosage), Lymphangiectasis, Intestinal (complications), Lymphangiectasis, Intestinal (diet therapy), Lymphangiectasis, Intestinal (drug therapy), Lymphedema (complications), Lymphedema (diet therapy), Lymphedema (drug therapy), Male, Protein-Losing Enteropathies (drug therapy), Protein-Losing Enteropathies (etiology).
- MESH :
- chemical , administration & dosage : Everolimus, Immunosuppressive Agents.
- complications : Lymphangiectasis, Intestinal, Lymphedema.
- diet therapy : Lymphangiectasis, Intestinal, Lymphedema.
- drug therapy : Lymphangiectasis, Intestinal, Lymphedema, Protein-Losing Enteropathies.
- etiology : Protein-Losing Enteropathies.
- Child, Diet, Fat-Restricted, Dose-Response Relationship, Drug, Follow-Up Studies, Humans, Male.
Abstract
Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is an exudative enteropathy resulting from morphologic abnormalities in the intestinal lymphatics. In this article, we describe a 12-year-old boy with PIL that led to protein-losing enteropathy characterized by diarrhea, hypoalbuminemia associated with edema (serum albumin level: 1.0 g/dL), and hypogammaglobulinemia (serum IgG level: 144 mg/dL). Severe hypoalbuminemia, electrolyte abnormalities, and tetany persisted despite a low-fat diet and propranolol. Everolimus (1.6 mg/m(2)/day) was added to his treatment as an antiangiogenic agent. With everolimus treatment, the patient's diarrhea resolved and replacement therapy for hypoproteinemia was less frequent. Hematologic and scintigraphy findings also improved (serum albumin level: 2.5 g/dL). There were no adverse reactions during the 12-month follow-up. To the best of our knowledge, this is the first report of everolimus use in a patient with PIL.
DOI: 10.1542/peds.2015-2562
PubMed: 26908672
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000988
- to stream PubMed, to step Curation: 000988
- to stream PubMed, to step Checkpoint: 000988
- to stream Ncbi, to step Merge: 007F25
- to stream Ncbi, to step Curation: 007F25
- to stream Ncbi, to step Checkpoint: 007F25
- to stream Main, to step Merge: 001094
- to stream Main, to step Curation: 001092
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Everolimus for Primary Intestinal Lymphangiectasia With Protein-Losing Enteropathy.</title><author><name sortKey="Ozeki, Michio" sort="Ozeki, Michio" uniqKey="Ozeki M" first="Michio" last="Ozeki">Michio Ozeki</name><affiliation wicri:level="1"><nlm:affiliation>Departments of Pediatrics, michioo@gifu-u.ac.jp.</nlm:affiliation><country wicri:rule="url">Japon</country><wicri:regionArea>Departments of Pediatrics</wicri:regionArea></affiliation></author><author><name sortKey="Hori, Tomohiro" sort="Hori, Tomohiro" uniqKey="Hori T" first="Tomohiro" last="Hori">Tomohiro Hori</name><affiliation><nlm:affiliation>Departments of Pediatrics.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatrics.</wicri:noCountry></affiliation></author><author><name sortKey="Kanda, Kaori" sort="Kanda, Kaori" uniqKey="Kanda K" first="Kaori" last="Kanda">Kaori Kanda</name><affiliation><nlm:affiliation>Departments of Pediatrics.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatrics.</wicri:noCountry></affiliation></author><author><name sortKey="Kawamoto, Norio" sort="Kawamoto, Norio" uniqKey="Kawamoto N" first="Norio" last="Kawamoto">Norio Kawamoto</name><affiliation><nlm:affiliation>Departments of Pediatrics.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatrics.</wicri:noCountry></affiliation></author><author><name sortKey="Ibuka, Takashi" sort="Ibuka, Takashi" uniqKey="Ibuka T" first="Takashi" last="Ibuka">Takashi Ibuka</name><affiliation><nlm:affiliation>Gastroenterology, and.</nlm:affiliation><wicri:noCountry code="subField">and</wicri:noCountry></affiliation></author><author><name sortKey="Miyazaki, Tatsuhiko" sort="Miyazaki, Tatsuhiko" uniqKey="Miyazaki T" first="Tatsuhiko" last="Miyazaki">Tatsuhiko Miyazaki</name><affiliation wicri:level="1"><nlm:affiliation>Pathology, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Pathology, Gifu University Graduate School of Medicine, Gifu University, Gifu</wicri:regionArea><wicri:noRegion>Gifu</wicri:noRegion></affiliation></author><author><name sortKey="Fukao, Toshiyuki" sort="Fukao, Toshiyuki" uniqKey="Fukao T" first="Toshiyuki" last="Fukao">Toshiyuki Fukao</name><affiliation><nlm:affiliation>Departments of Pediatrics.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatrics.</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26908672</idno><idno type="pmid">26908672</idno><idno type="doi">10.1542/peds.2015-2562</idno><idno type="wicri:Area/PubMed/Corpus">000988</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000988</idno><idno type="wicri:Area/PubMed/Curation">000988</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000988</idno><idno type="wicri:Area/PubMed/Checkpoint">000988</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000988</idno><idno type="wicri:Area/Ncbi/Merge">007F25</idno><idno type="wicri:Area/Ncbi/Curation">007F25</idno><idno type="wicri:Area/Ncbi/Checkpoint">007F25</idno><idno type="wicri:Area/Main/Merge">001094</idno><idno type="wicri:Area/Main/Curation">001092</idno><idno type="wicri:Area/Main/Exploration">001092</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Everolimus for Primary Intestinal Lymphangiectasia With Protein-Losing Enteropathy.</title><author><name sortKey="Ozeki, Michio" sort="Ozeki, Michio" uniqKey="Ozeki M" first="Michio" last="Ozeki">Michio Ozeki</name><affiliation wicri:level="1"><nlm:affiliation>Departments of Pediatrics, michioo@gifu-u.ac.jp.</nlm:affiliation><country wicri:rule="url">Japon</country><wicri:regionArea>Departments of Pediatrics</wicri:regionArea></affiliation></author><author><name sortKey="Hori, Tomohiro" sort="Hori, Tomohiro" uniqKey="Hori T" first="Tomohiro" last="Hori">Tomohiro Hori</name><affiliation><nlm:affiliation>Departments of Pediatrics.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatrics.</wicri:noCountry></affiliation></author><author><name sortKey="Kanda, Kaori" sort="Kanda, Kaori" uniqKey="Kanda K" first="Kaori" last="Kanda">Kaori Kanda</name><affiliation><nlm:affiliation>Departments of Pediatrics.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatrics.</wicri:noCountry></affiliation></author><author><name sortKey="Kawamoto, Norio" sort="Kawamoto, Norio" uniqKey="Kawamoto N" first="Norio" last="Kawamoto">Norio Kawamoto</name><affiliation><nlm:affiliation>Departments of Pediatrics.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatrics.</wicri:noCountry></affiliation></author><author><name sortKey="Ibuka, Takashi" sort="Ibuka, Takashi" uniqKey="Ibuka T" first="Takashi" last="Ibuka">Takashi Ibuka</name><affiliation><nlm:affiliation>Gastroenterology, and.</nlm:affiliation><wicri:noCountry code="subField">and</wicri:noCountry></affiliation></author><author><name sortKey="Miyazaki, Tatsuhiko" sort="Miyazaki, Tatsuhiko" uniqKey="Miyazaki T" first="Tatsuhiko" last="Miyazaki">Tatsuhiko Miyazaki</name><affiliation wicri:level="1"><nlm:affiliation>Pathology, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Pathology, Gifu University Graduate School of Medicine, Gifu University, Gifu</wicri:regionArea><wicri:noRegion>Gifu</wicri:noRegion></affiliation></author><author><name sortKey="Fukao, Toshiyuki" sort="Fukao, Toshiyuki" uniqKey="Fukao T" first="Toshiyuki" last="Fukao">Toshiyuki Fukao</name><affiliation><nlm:affiliation>Departments of Pediatrics.</nlm:affiliation><wicri:noCountry code="no comma">Departments of Pediatrics.</wicri:noCountry></affiliation></author></analytic><series><title level="j">Pediatrics</title><idno type="eISSN">1098-4275</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Child</term><term>Diet, Fat-Restricted</term><term>Dose-Response Relationship, Drug</term><term>Everolimus (administration & dosage)</term><term>Follow-Up Studies</term><term>Humans</term><term>Immunosuppressive Agents (administration & dosage)</term><term>Lymphangiectasis, Intestinal (complications)</term><term>Lymphangiectasis, Intestinal (diet therapy)</term><term>Lymphangiectasis, Intestinal (drug therapy)</term><term>Lymphedema (complications)</term><term>Lymphedema (diet therapy)</term><term>Lymphedema (drug therapy)</term><term>Male</term><term>Protein-Losing Enteropathies (drug therapy)</term><term>Protein-Losing Enteropathies (etiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Enfant</term><term>Entéropathie exsudative (traitement médicamenteux)</term><term>Entéropathie exsudative (étiologie)</term><term>Humains</term><term>Immunosuppresseurs (administration et posologie)</term><term>Lymphangiectasie intestinale ()</term><term>Lymphangiectasie intestinale (diétothérapie)</term><term>Lymphangiectasie intestinale (traitement médicamenteux)</term><term>Lymphoedème ()</term><term>Lymphoedème (diétothérapie)</term><term>Lymphoedème (traitement médicamenteux)</term><term>Mâle</term><term>Relation dose-effet des médicaments</term><term>Régime pauvre en graisses</term><term>Études de suivi</term><term>Évérolimus (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Everolimus</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Immunosuppresseurs</term><term>Évérolimus</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lymphangiectasis, Intestinal</term><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="diet therapy" xml:lang="en"><term>Lymphangiectasis, Intestinal</term><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="diétothérapie" xml:lang="fr"><term>Lymphangiectasie intestinale</term><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphangiectasis, Intestinal</term><term>Lymphedema</term><term>Protein-Losing Enteropathies</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Protein-Losing Enteropathies</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Entéropathie exsudative</term><term>Lymphangiectasie intestinale</term><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Entéropathie exsudative</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Diet, Fat-Restricted</term><term>Dose-Response Relationship, Drug</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Enfant</term><term>Humains</term><term>Lymphangiectasie intestinale</term><term>Lymphoedème</term><term>Mâle</term><term>Relation dose-effet des médicaments</term><term>Régime pauvre en graisses</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Primary intestinal lymphangiectasia (PIL), also known as Waldmann's disease, is an exudative enteropathy resulting from morphologic abnormalities in the intestinal lymphatics. In this article, we describe a 12-year-old boy with PIL that led to protein-losing enteropathy characterized by diarrhea, hypoalbuminemia associated with edema (serum albumin level: 1.0 g/dL), and hypogammaglobulinemia (serum IgG level: 144 mg/dL). Severe hypoalbuminemia, electrolyte abnormalities, and tetany persisted despite a low-fat diet and propranolol. Everolimus (1.6 mg/m(2)/day) was added to his treatment as an antiangiogenic agent. With everolimus treatment, the patient's diarrhea resolved and replacement therapy for hypoproteinemia was less frequent. Hematologic and scintigraphy findings also improved (serum albumin level: 2.5 g/dL). There were no adverse reactions during the 12-month follow-up. To the best of our knowledge, this is the first report of everolimus use in a patient with PIL.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Fukao, Toshiyuki" sort="Fukao, Toshiyuki" uniqKey="Fukao T" first="Toshiyuki" last="Fukao">Toshiyuki Fukao</name><name sortKey="Hori, Tomohiro" sort="Hori, Tomohiro" uniqKey="Hori T" first="Tomohiro" last="Hori">Tomohiro Hori</name><name sortKey="Ibuka, Takashi" sort="Ibuka, Takashi" uniqKey="Ibuka T" first="Takashi" last="Ibuka">Takashi Ibuka</name><name sortKey="Kanda, Kaori" sort="Kanda, Kaori" uniqKey="Kanda K" first="Kaori" last="Kanda">Kaori Kanda</name><name sortKey="Kawamoto, Norio" sort="Kawamoto, Norio" uniqKey="Kawamoto N" first="Norio" last="Kawamoto">Norio Kawamoto</name></noCountry><country name="Japon"><noRegion><name sortKey="Ozeki, Michio" sort="Ozeki, Michio" uniqKey="Ozeki M" first="Michio" last="Ozeki">Michio Ozeki</name></noRegion><name sortKey="Miyazaki, Tatsuhiko" sort="Miyazaki, Tatsuhiko" uniqKey="Miyazaki T" first="Tatsuhiko" last="Miyazaki">Tatsuhiko Miyazaki</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001092 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001092 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26908672
|texte= Everolimus for Primary Intestinal Lymphangiectasia With Protein-Losing Enteropathy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26908672" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |